Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

ABSTRACT:

Background

We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs).

Methods

Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of eight cycles containing carboplatin were administered.

Results

All women (N=87) had good performance status and end-organ function. Incidences of carboplatin HSR before enrolment and on study were 17% and 21%, respectively. Most patients who developed carboplatin HSR had a deleterious BRCA1/2 mutation (93%) vs 50% in patients without HSR (P<0.0001). Multivariable analysis accounting for potential confounding variables including age, history of allergies, and cumulative prior ca

SUBMITTER: Moon DH 

PROVIDER: S-EPMC3749564 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature